| T cell reactivity against the SmD183–119 C terminal peptide in patients with systemic lupus erythematosus | |||||||||||
Abstract | |||||||||||
| Background: The SmD183–119 peptide is a major target of the B cell response in patients with systemic lupus erythematosus (SLE). | |||||||||||
Publication details | |||||||||||
| |||||||||||